Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read more...] about Geron: The Neverending Story
Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
You must be logged in to post a comment.